Theravance Biopharma News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.11.17	Theravance Biopharma, Inc. Reports Third Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
01.11.17	Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17	Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting (PR Newswire)
01.11.17	Theravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland (PR Newswire)
01.11.17	Theravance Biopharma Announces Opening of Company's New Corporate Office in Dublin, Ireland (PR Newswire)
31.10.17	Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR™ Observational Patient Registry at 2017 CHEST Annual Meeting (PR Newswire)
30.10.17	Theravance Biopharma to Report Third Quarter 2017 Financial Results on November 7, 2017 (PR Newswire)
25.10.17	CLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On Watch (RTTNews)
24.10.17	Theravance Biopharma to Present New Data from Studies of VIBATIV® (telavancin) and Revefenacin (TD-4208) at the 2017 CHEST Annual Meeting (PR Newswire)
09.10.17	Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 (PR Newswire)
03.10.17	Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek™ 2017 (PR Newswire)
20.09.17	Theravance Biopharma Highlights Positive Headline Results from IMPACT Study of Trelegy Ellipta Announced by GlaxoSmithKline and Innoviva (PR Newswire)
19.09.17	Theravance Biopharma to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire)
19.09.17	Theravance Biopharma Highlights Approval of Trelegy Ellipta (Closed Triple) as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US (PR Newswire)
19.09.17	TIBCO Connected Intelligence Cloud Equips Companies for Digital Transformation (PR Newswire)
18.09.17	Theravance Biopharma Highlights GlaxoSmithKline and Innoviva's Receipt of Positive Opinion from CHMP in Europe for Trelegy Ellipta (Closed Triple) (PR Newswire)
05.09.17	Theravance Biopharma to Present at the Morgan Stanley 15th Annual Global Healthcare Conference (PR Newswire)
15.08.17	Gainers & Losers Of Aug.14: TTOO, TBPH, SGMO, APEN, ZYNE... (RTTNews)
10.08.17	Gainers & Losers Of Aug.9: NTRA, ACHN, OMER, SGRY, PGNX... (RTTNews)
09.08.17	ACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq (RTTNews)
08.08.17	Theravance Biopharma, Inc. Reports Second Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
08.08.17	Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis (PR Newswire)
03.08.17	FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps (RTTNews)
02.08.17	Theravance Biopharma Announces Positive Top-Line Results from Phase 2b Study of Velusetrag (TD-5108) in Patients with Gastroparesis (PR Newswire)
01.08.17	Theravance Biopharma to Report Second Quarter 2017 Financial Results and Business Update on August 8, 2017 (PR Newswire)
31.07.17	Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy (PR Newswire)
20.07.17	SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz (RTTNews)
19.07.17	Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
19.07.17	Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
05.06.17	New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017 (PR Newswire)
23.05.17	Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
23.05.17	Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
17.05.17	Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS (PR Newswire)
10.05.17	ARRY Hits Trial Goals, DEPO Falls On Q1 Results, SAGE Awaits Data In Q3 (RTTNews)
09.05.17	Theravance Biopharma, Inc. Reports First Quarter 2017 Financial Results and Provides Business Update (PR Newswire)
02.05.17	Theravance Biopharma to Report First Quarter 2017 Financial Results on May 9, 2017 (PR Newswire)
27.04.17	Theravance Biopharma to Present at the Deutsche Bank 42nd Annual Health Care Conference (PR Newswire)
25.04.17	New Data for VIBATIV® (telavancin) Reported in Several Presentations at ECCMID 2017 (PR Newswire)
24.04.17	Theravance Biopharma Reports Positive Clinical Response Rates for Patients in TOUR™ Observational Patient Registry in Several Presentations at ECCMID 2017 (PR Newswire)
18.04.17	Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin), Including Preliminary Results from TOUR™ Observational Patient Registry, at 2017 ECCMID Conference (PR Newswire)
13.04.17	Nintex Announces 6th Annual Partner Awards (PR Newswire)
28.03.17	Theravance Biopharma to Present at the 16th Annual Needham Healthcare Conference (PR Newswire)
17.02.17	Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn's and Colitis Organization (PR Newswire)
15.02.17	Theravance Biopharma to Report Fourth Quarter and Full Year 2016 Financial Results on February 27, 2017 (PR Newswire)
02.02.17	Theravance Biopharma to Present at the Leerink Partners 6th Annual Global Healthcare Conference (PR Newswire)
23.01.17	Theravance Biopharma Reports New Data from Ongoing TOUR™ Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress (PR Newswire)
20.01.17	Research Reports Initiation on Biotech Stocks -- Regulus Therapeutics, Abeona Therapeutics, Theravance Biopharma, and Sage Therapeutics (PR Newswire)
17.01.17	Theravance Biopharma to Present New Data from Ongoing TOUR™ Observational Patient Registry at SCCM Critical Care Congress (PR Newswire)
19.12.16	Theravance Biopharma Highlights Initiation of Phase 3 Study of the Closed Triple in Patients with Asthma by GlaxoSmithKline and Innoviva (PR Newswire)
05.12.16	Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Theravance Biopharma Inc When Issued

Aktien Top/Flop

Meistgelesene Nachrichten